You are here

Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL164260-01
Agency Tracking Number: R41HL164260
Amount: $274,441.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA21-262
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-09-22
Award End Date (Contract End Date): 2023-09-21
Small Business Information
Sykesville, MD 21784-8213
United States
DUNS: 117951622
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (301) 983-3780
Business Contact
Phone: (815) 529-8777
Research Institution
Office of Contract and Grant Administration 9500 Gilman Drive, Mail Code 0934
LA JOLLA, CA 92093-0934
United States

 Nonprofit College or University

ABSTRACTAlpha-1 antitrypsin (A1AT) is well-established as a biotherapeutic used for the treatment of alpha-1
antitrypsin deficiency, and shows promise for treating a variety of other diseases. However, A1AT augmentation
therapy carries unnecessary risk since it relies upon the weekly transfusion of plasma-derived product, which
presents supply chain and contaminant risks. This could be remedied with recombinant A1AT, if it adequately
matches or improves upon the plasma-derived product, including its post-translational modifications and
functional attributes. However, major hurdles to the development of recombinant A1AT exist, since post-
translational modifications, such as glycosylation, impact drug activities and half-life, and it has remained
challenging to match glycosylation of recombinant A1AT to the plasma derived isoforms. Here we developed a
large panel of diverse GMP-ready glycoengineered CHO (geCHO) cell lines that allowed us to discover a host
cell line, geCHO-L, that matches glycosylation of the plasma derived product. Here we will demonstrate our
platform not only allows us to identify a CHO clone matches the glycosylation of the approved product, but that
we can also match the function and half-life of the approved A1AT to enable the manufacturing of a recombinant
A1AT to increase the safety and protect the supply of therapeutic A1AT. We further engineer the recombinant
A1AT to obtain a product with improved activity and half-life as a candidate therapeutic for alpha-1 antitrypsin
deficiency and other diseases.PROJECT NARRATIVEAlpha-1 antitrypsin (A1AT) deficiencies require replacement therapies derived from blood plasma, but
recombinant expression systems have limited the ability to produce safer recombinant A1AT matching the
approved drug. Using engineered CHO cells and further protein engineering, we develop effective production of
recombinant A1AT matching and exceeding plasma-derived product in quality, efficacy, safety and half-life,
yielding a safe and reliable drug source.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government